Lorlatinib: a new-generation drug for ALK-positive NSCLC

Research output: Contribution to journalComment/debate

4 Scopus citations
Original languageEnglish
Pages (from-to)1555-1557
Number of pages3
JournalThe Lancet Oncology
Volume19
Issue number12
DOIs
StatePublished - Dec 2018

Cite this